3M Drug Delivery Systems has announced that it is manufacturing the authorized generic of Proventil HFA that was recently launched by Par Pharmaceutical. Proventil HFA, which is also manufactured by 3M, is marketed by Merck. 3M DDS Global Business Leader Keith O-Connor commented, “3M Drug Delivery Systems is proud to work with Par to offer patients a lower list … [Read more...] about 3M announces that it is manufacturing authorized generic of Proventil HFA
Business
Satsuma Pharmaceuticals raises $62 million for development of intranasal DHE
Satsuma Pharmaceuticals said that it has raised $62 million in Series B financing that will be used for Phase 3 development of its STS101 intranasal dry powder dihydroergotamine (DHE) for the treatment of migraines. Satsuma was spun off from SNBL in 2017 specifically to develop STS101 and at the time raised $12 million in Series A financing. Earlier this year, the … [Read more...] about Satsuma Pharmaceuticals raises $62 million for development of intranasal DHE
Boehringer Ingelheim completes expansion of Respimat manufacturing facilities
Boehringer Ingelheim said recently that it has completed a €105 million expansion of its facilities in Dortmund and Ingelheim, Germany to increase manufacturing capacity for its Respimat soft mist inhaler. The company said that the expansion has been completed in time to support its launch of a next generation Respimat in Europe this year. The new Respimat is … [Read more...] about Boehringer Ingelheim completes expansion of Respimat manufacturing facilities
FDA approves Akorn’s ANDA for fluticasone propionate nasal spray
Akorn announced that the FDA has approved an ANDA for fluticasone propionate nasal spray submitted by Hi Tech Pharmacal, which was acquired by Akorn in 2014. The nasal spray is a generic of GSK's Flonase, which was approved for OTC sales in the US in 2014. Akorn President and CEO Douglas Boothe said, “We are excited to add to our fluticasone franchise and look … [Read more...] about FDA approves Akorn’s ANDA for fluticasone propionate nasal spray
Pulmatrix and Cip Tec enter into definitive agreement for Pulmazole
Following Pulmatrix's recent successful public offering, Pulmatrix and Cipla subsidiary Cipla Technologies (Cip Tec) have entered into a definitive agreement in which Cipla will acquire rights to the Pulmazole itraconazole DPI for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in asthma patients. The companies had previously announced terms of the … [Read more...] about Pulmatrix and Cip Tec enter into definitive agreement for Pulmazole
Cipla launches Niveoli MDI in India
Cipla Limited has announced the launch of its Niveoli extra-fine particle beclomethasone/formoterol fumarate MDI for the treatment of asthma and COPD in adults in India. Cipla India Business Head Nikhil Chopra commented, “Cipla is pleased to offer yet another milestone in respiratory inhalation therapy. Niveoli marks a first in acknowledging and addressing the issue … [Read more...] about Cipla launches Niveoli MDI in India
Insmed gets additional US patent for Arikayce inhalation suspension
Insmed Incorporated said that the U.S. Patent and Trademark Office (USPTO) has issued US patent No. 10,251,900, titled "Methods for treating pulmonary non-tuberculous mycobacterial infections," which is the 10th US patent covering the use of Arikayce amikacin liposome inhalation suspension for the treatment of Mycobacterium avium complex (MAC) lung disease. Arikayce … [Read more...] about Insmed gets additional US patent for Arikayce inhalation suspension
Noveome Biotherapeutics raises $15 million for development of ST266
Noveome Biotherapeutics said that it has closed a $15 million Series D financing round that will help to fund further development of its ST266 biologic. Intranasal formulations of ST266 are in development for the treatment of optic nerve disease and for chronic traumatic encephalopathy (CTE). In 2017, Noveome announced positive data from a preclinical study of … [Read more...] about Noveome Biotherapeutics raises $15 million for development of ST266
Otitopic announces plans to develop its inhaled aspirin for the treatment of lung cancer
Otitopic, which recently announced that it received a new patent for the us of inhaled aspirin for the treatment of myocardial infarction, now says that it also plans to develop its Asprihale aspirin DPI for the treatment of lung cancer. The company cites published studies showing lower risk of lung cancer with aspirin use and the potential of aspirin to inhibit … [Read more...] about Otitopic announces plans to develop its inhaled aspirin for the treatment of lung cancer
Pulmatrix raises $16.6 million in public offering
Pulmatrix said that it has closed a public offering with expected gross proceeds of $16.6 million that will be used primarily for development of its inhaled therapies, especially Pulmazole inhaled itraconazole for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in asthma patients. The company had previously said that it expected to raise $14.4 … [Read more...] about Pulmatrix raises $16.6 million in public offering